<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00494039</url>
  </required_header>
  <id_info>
    <org_study_id>IP</org_study_id>
    <nct_id>NCT00494039</nct_id>
  </id_info>
  <brief_title>I-125 Versus Pd-103 for Low Risk Prostate Cancer</brief_title>
  <official_title>I-125 Versus Pd-103 for Low Risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Puget Sound Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schiffler Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Puget Sound Health Care System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To test the hypothesis that the shorter half-life of Pd-103 versus I-125, will
      increase the rate of tumor eradication.

      Research design A total of 600 patients with AJC clinical stage T1c-T2a prostatic carcinoma
      (Gleason grade 2 to 6, PSA 4 to 10 ng/ml) will be randomized to implantation with I-125 (160
      Gy) versus Pd-103 (115 Gy).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To test the hypothesis that the shorter half-life of Pd-103 versus I-125, will
      increase the rate of tumor eradication.

      Research design A total of 600 patients with AJC clinical stage T1c-T2a prostatic carcinoma
      (Gleason grade 2 to 6, PSA 4 to 10 ng/ml) will be randomized to implantation with I-125 (160
      Gy) versus Pd-103 (115 Gy).

      Methodology: Patients will be randomized by the method of random permuted blocks.

      Cancer status will be monitored by serial serum PSA at 6, 12, 18 and 24 months and yearly
      thereafter. Treatment-related morbidity will be monitored by personal interview, using
      standard American Urologic Association and Radiation Therapy Oncology Group criteria at 1, 3,
      6, 12 and 24 months. Patients with serum PSA above 1.0 ng/ml two years after treatment will
      be considered to have residual or recurrent cancer and to have failed therapy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 1998</start_date>
  <completion_date type="Anticipated">January 2010</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cancer control (biochemical and survival)</measure>
    <time_frame>final analysis 2008(?)</time_frame>
  </primary_outcome>
  <enrollment type="Actual">602</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radioactive seed implant to prostate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males age 40-80

          -  PSA 4-10

          -  Gleason score 5-6

        Exclusion Criteria:

          -  Lymph node positive
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kent E Wallner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Puget Sound Health Care system</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Puget Sound VA</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Wallner K, Merrick G, True L, Sutlief S, Cavanagh W, Butler W. 125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial. Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1297-303.</citation>
    <PMID>14630265</PMID>
  </results_reference>
  <results_reference>
    <citation>Wallner K, Merrick G, True L, Cavanagh W, Simpson C, Butler W. I-125 versus Pd-103 for low-risk prostate cancer: morbidity outcomes from a prospective randomized multicenter trial. Cancer J. 2002 Jan-Feb;8(1):67-73.</citation>
    <PMID>11895205</PMID>
  </results_reference>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2007</study_first_submitted>
  <study_first_submitted_qc>June 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2007</study_first_posted>
  <last_update_submitted>June 28, 2007</last_update_submitted>
  <last_update_submitted_qc>June 28, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2007</last_update_posted>
  <keyword>prostate</keyword>
  <keyword>cancer</keyword>
  <keyword>radiation</keyword>
  <keyword>brachytherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

